Articles Archives
Articles
05/26/2026
Cryoport Systems in Labiotech on Where CGT Supply Chains Start to Break
As more cell and gene therapy programs push toward later-stage trials and commercialization, a familiar set of pressures is starting to surface. What once felt manageable at smaller scale begins to take more effort to hold together as volumes pick up. A recent article in Labiotech, developed in collaboration with Cryoport Systems, looks closely at where that strain comes from and how it often traces back to decisions made much earlier in development.
Articles
05/26/2026
Matthew Plaud on Building Supply Chains that Actually Scale
In a recent conversation with Contract Pharma, Matthew Plaud, COO of IntegriCell® at Cryoport Systems, discussed where advanced therapy supply chains stand today, and where they start to strain as programs move toward commercialization.
Industry Insights
04/14/2026
Building Global Readiness: Key Takeaways from Matthew Frazzetta at Hope Is Not a Workflow
As cell and gene therapies continue to advance scientifically, operational readiness is increasingly determining whether those therapies reach patients at scale. During a presentation at Hope Is Not a Workflow, Matthew Frazzetta, Vice President of Global Accounts for BioServices at Cryoport Systems, addressed a question that is becoming impossible for the industry to ignore: How do we build a global, standardized, and scalable supply chain capable of supporting the next generation of advanced therapies?
Industry Insights
04/13/2026
What Will It Take to Move Cell Therapy Forward? Reflections from the Hope Is Not a Workflow Panel
At the recent Hope Is Not a Workflow event, industry leaders came together to tackle some of the most persistent questions facing cell and gene therapy today. During a panel, Dominic Clarke (VP, IntegriCell® Technical Operations, Cryoport Systems) joined the discussion to share his perspective on what is slowing adoption and what it will take to move the industry forward in a meaningful way.
Managing the Cold Chain
03/19/2026
Advance Program Stability by Building Cryopreservation Into the System, Not Around It
Cryopreservation has become a practical way for early programs to give themselves more room to plan, especially when collection schedules don’t line up neatly with manufacturing availability. How the material actually enters the frozen state, though, has a noticeable influence on what teams see later in development. When sites follow their own methods or adapt the process to local routines, those differences show up in the frozen material and stay with it.
Industry Insights
12/19/2025
Expert Q&A: Is Standardization the Bottleneck or Breakthrough to Building Scalable and Cost-Effective CGT Programs?
Cell and gene therapy (CGT) companies are under constant pressure to do more while hitting milestones earlier. Demonstrate manufacturability. Ensure regulatory readiness. Design for scalability and patient access. And do all of this with more constrained resources and increasingly aggressive timelines. Building on our recent panel discussion, we gathered extended perspectives from Dr. Don Fink (Dark Horse Consulting Group), Audrey Greenberg (Mayo Venture Partners), Dr. Dominic Clarke (Cryoport Systems), and Kurtis Carlisle (Cabaletta Bio).
Navigating Logistics
12/16/2025
Driving Compliance and Standardization in CGT Supply Chains
As cell and gene therapies (CGTs) continue to advance and more therapies reach late-stage clinical trials and commercialization, the complexity of the related logistics is only increasing. Therapies are crossing borders, reaching broader patient populations, and expanding into global distribution, all of which introduces risk if standards are inconsistent. Compliance and standardization, as a result, are essential for ensuring both scalability and patient safety.
Navigating Logistics
12/11/2025
Setting the Benchmark for Quality in Cell and Gene Therapy Logistics
Quality in cell and gene therapy (CGT) is the foundation that determines whether a therapy reaches a patient intact and effective. As the industry increasingly scales from early development of CGTs to global commercialization, the margin for error narrows as volume and complexity increase. Standards like ISO 21973 provide a framework, but true industry leadership comes from how those standards are applied. In this, Cryoport Systems is setting that benchmark.
Navigating Logistics
10/22/2025